Outcome of board meeting held on Friday 13, 2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 10.5 pts less than Nifty Microcap 250 and 10.8 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Coral Laboratories' board, meeting on February 13, 2026, approved unaudited standalone financial results for Q3 FY26 (quarter ended Dec 31, 2025) and the nine-month period, which were also subject to a limited review by statutory auditor M/s S. C. Mehra & Associates LLP. Revenue from operations for Q3 FY26 came in at Rs. 2,156.42 lakhs, down about 6% from Rs. 2,298.61 lakhs in Q3 FY25, while nine-month revenue fell sharply to Rs. 5,942.04 lakhs from Rs. 8,687.06 lakhs, a drop of roughly 32% year-on-year. Net profit for the quarter dropped to Rs. 277.55 lakhs (from Rs. 614.45 lakhs in Q3 FY25), and nine-month profit nearly halved to Rs. 1,115.74 lakhs (from Rs. 2,132.86 lakhs), with EPS falling to Rs. 31.23 from Rs. 59.70. Operating margins compressed materially, reflecting higher input costs and inventory adjustments, and a small exceptional item of Rs. 32.25 lakhs (prior-year tax provision) was also booked in the nine-month figures.
Shareholders should note a significant slowdown in both top line and bottom line compared with last year, with revenue and profits both contracting sharply on a nine-month basis — likely to weigh on short-term sentiment despite the company still remaining profitable.